ATS 2024 Final Program

Click on the session title to view the speakers

164

MONDAY • MAY 20

P10 Nonsynonymous Genetic Variant Burden in Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease P11 Pulmonary Artery Pulsatility Index (PAPI) as a Predictor of Mortality in Pulmonary Hypertension-associated Interstitial Lung Disease (PH-ILD) P12 New European Society of Cardiology Definition of Severe Pulmonary Hypertension Predicts Mortality in Patients With Idiopathic Pulmonary Fibrosis P13 Characterization of Cardiopulmonary Exercise Testing Profiles for Patients With Pulmonary Hypertension and Interstitial Lung Disease P14 Does the Change in RV Strain During Sub-maximal Exercise Contribute to Exercise Intolerance Among Post 9/11 Veterans With Airborne Hazards and Burn Pits Exposure? P15 Pulmonary Vasodilatory Therapy in Patients With Chronic Obstructive Pulmonary Disease-mediated Pulmonary Hypertension P16 Temporal Progression of Early Smoke-induced Pulmonary Vascular Alterations in COPD-associated Pulmonary Hypertension P17 Qualitative Concept Elicitation Interviews With Patients and Expert Clinicians to Explore the Patient Experience of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (PH-COPD) P18 Significance of Adma Levels in Patients With Pulmonary Hypertension and Chronic Kidney Disease P19 ILD/CPFE With Severe WHO Group III PH Patients Referred to Transplant Center for Evaluation: An Observational Study P20 Effect of Updated European Society of Cardiology Pulmonary Hypertension Diagnostic Criteria on Lung Transplantation Waitlist Outcomes in Hypersensitivity Pneumonitis Patients Listed for Lung Transplantation P21 Effect of Pulmonary Vasodilator Therapy on Survival and Functional Outcomes in Patient With Combined Pulmonary Fibrosis and Emphysema and Pulmonary Hypertension

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B60 CYANOTIC PACIFIC BLUE: GROUP 3 PH AND HYPOXIC LUNG DISEASE 9:15 a.m. - 4:15 p.m. San Diego Convention Center Area A (Hall A-B2, Ground Level) Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P1 The Relationship Between Respiratory Mechanics Hypertension Undergoing Invasive Cardio-pulmonary Exercise Testing P2 Right Ventricular Dysfunction and Its Clinical Significance in Group 3 Pulmonary Hypertension P3 Prognostic Limitations for Who Group 3 Pulmonary Hypertension Patients - A Retrospective Study P4 Real World Outcomes of Inhaled Treprostinil in Group 3 Pulmonary Hypertension P5 Patients With Chronic Obstructive Pulmonary Disease and Associated Pulmonary Hypertension Demonstrate Reduction in Exertional Ventricular-arterial Coupling: A Pilot Study Utilizing Invasive Cardiopulmonary Exercise Testing P6 uniPHied: A Novel Platform Study Design for a and Pulmonary Capillary Wedge Pressure in Patients With COPD-associated Pulmonary P7 Unveiling Right Heart Hemodynamics and Treatment Response in Pulmonary Hypertension Patients With Obstructive Sleep Apnea: A Community-centered Perspective P8 Clinical Significance of Updated Pulmonary Hypertension Guidelines on Combined Pulmonary Fibrosis and Emphysema (CPFE) P9 Prevalence of Pulmonary Hypertension in Patients With Chronic Hypercapnic Respiratory Failure: A Retrospective Study Phase 2 Clinical Trial to Assess the Safety and Efficacy of AER-901 in Pulmonary Hypertension Associated With Interstitial Lung Disease and Pulmonary Arterial Hypertension

ATS 2024 Conference Program • San Diego, CA